Burning Rock Biotech Ltd SEC Filings

Welcome to our dedicated page for Burning Rock Biotech SEC filings (Ticker: BNR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Burning Rock Biotech Limited (NASDAQ: BNR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Burning Rock files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission, covering its precision oncology business based on next generation sequencing (NGS) technology.

In these filings, Burning Rock presents detailed information on its three operating segments: central laboratory business, in-hospital business and pharma research and development services. Investors can review segment revenues, gross profit, operating expenses and discussions of the company’s use of non-GAAP measures such as non-GAAP gross profit and non-GAAP gross margin, which exclude depreciation and amortization.

Form 6-K submissions often incorporate press releases by reference, including quarterly financial results, business updates and information on regulatory milestones. These may describe developments in NGS-based therapy selection testing for late-stage cancer patients, cancer early detection programs that have entered clinical validation, and global pharmaceutical services on biomarker detection and companion diagnostics development.

Through Stock Titan, users can track Burning Rock’s real-time filings as they are furnished to the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents, highlighting items such as segment performance, geographic revenue breakdowns, and updates on regulatory approvals or collaborations related to companion diagnostics. The filings page is a resource for understanding how Burning Rock describes its business model, financial condition and risk factors in official U.S. securities filings connected to BNR stock.